Assessment of anti‐SARS‐CoV‐2 antibodies level in convalescents plasma
Open Access
- 9 November 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 1130-1137
Abstract
Despite extensive vaccination, the quantity of patients infected with the SARS‐CoV‐2 virus and its variants continues to grow worldwide. Treating patients with a severe course of COVID‐19 is a difficult challenge. One of the generally accepted and specific therapy methods is the use of plasma rich in anti‐SARS‐CoV‐2 antibodies. On the other hand, assessing the antibodies level depending on the time after infection allows for vaccine‐decision. The study marked the level of anti‐SARS‐CoV‐2 IgG antibodies in 351 COVID‐19 convalescent residents of one geographical region in Poland. The study group included blood donors. The studies were cross‐sectional and extended to a questionnaire to determine infection severity. These data were compiled statistically. The study considered epidemiological factors, the time from the end of the infection, and infection severity. The fastest increase of the antibodies level was observed up to 59 days after COVID‐19, and it was statistically significantly higher among men. Higher levels of antibodies were found among people above the average age in both men and women. There was an increase in the level of antibodies since the onset of the disease in men, while in women, it decreased. The antibodies level was also found to depend on the severity of the course of COVID‐19 infection. The optimal group of plasma donors in the studied geographical region is men and women above 39 years old. after a more severe infection. The titer of antibodies increases with time from the disease.Keywords
This publication has 18 references indexed in Scilit:
- Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 PatientsJournal of Clinical Medicine, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Considering how biological sex impacts immune responses and COVID-19 outcomesNature Reviews Immunology, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- The convalescent sera option for containing COVID-19Journal of Clinical Investigation, 2020
- Hark back: Passive immunotherapy for influenza and other serious infectionsCritical Care Medicine, 2010
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Endemic lassa fever in liberia. IV. Selection of optimally effective plasma for treatment by passive immunizationTransactions of the Royal Society of Tropical Medicine and Hygiene, 1985
- Hemophilus influenzae(Pfeiffer Bacillus) Meningitis and Its Specific TreatmentNew England Journal of Medicine, 1937
- THE USE OF FRESH HUMAN SERUM (COMPLEMENT) IN MENINGOCOCCUS MENINGITISJAMA, 1933